Flow cytometry service: panel design, controls and the data you get back

What to agree in advance

1. Panel design and who owns it. Establish whether the provider designs the panel, validates one you supply, or runs an existing catalogue panel, and who owns the design afterwards. A panel is a real piece of work and its ownership should not be discovered at the end of a study.
2. Sample type, stability and shipping. Fresh whole blood, isolated cells and fixed samples each have a stability window and a shipping requirement, and a sample outside its window produces data that looks real and is not. Agree the window, the shipper, the courier and what happens to a late arrival before anything ships.
3. Controls, agreed and paid for. Single stain compensation controls, fluorescence minus one controls where gates are ambiguous, viability discrimination and an isotype or biological negative where appropriate. These consume samples and instrument time and must be in the scope rather than assumed.
4. Instrument standardisation across a long study. For a study running months, ask how the provider standardises instruments over time with beads and how a service event or a laser replacement is handled. Without that, drift becomes an apparent biological effect.
5. Data delivery, including the raw files. Require the raw acquisition files as well as the analysis, with the gating strategy documented. A summary table alone cannot be re-examined, and re-analysis is exactly what you will want when a result is surprising.

Gating is an interpretation

Where gates are placed changes the numbers, and two competent analysts can gate the same file differently. Agree the gating strategy up front, require it documented, and have the same analyst or the same automated approach applied across a study.

For anything comparative, ask whether analysis can be blinded to group. It costs nothing and removes a class of criticism that is otherwise hard to answer.

In house or outsourced

Outsourcing suits occasional work, panels beyond your instrument's configuration, and studies needing standardisation you cannot provide. Keeping it in house suits routine work and anything where the turnaround of shipping would slow the science.

A common arrangement is routine panels in house and large or complex panels outsourced, which keeps the skill in the laboratory while buying capability it does not own.

A ccr6 antibody and a chemokine receptor on subsets

CCR6 marks particular T helper and B cell subsets, so a ccr6 antibody is read as part of a panel that defines the population and the expression is graded rather than binary. Receptors internalise on ligand exposure, so handling and any stimulation change the surface level. Antibodies against this family vary in specificity, so a knockout or a blocking control is worth having.

A lilrb2 antibody and an inhibitory receptor family

LILRB2 belongs to a family of closely related inhibitory receptors with activating counterparts, so a lilrb2 antibody must be specific within that family for a conclusion to hold, and the datasheet should say what it was tested against. Expression is on myeloid cells and changes with differentiation, which is why the maturation state belongs in the method.

An ido1 antibody and an enzyme induced by interferon

IDO1 is induced rather than constitutive, so an ido1 antibody reports a condition and an unstimulated control is what makes a positive meaningful. Its product rather than the protein is the functional readout, measured as the kynurenine to tryptophan ratio. In tissue the stain is cytoplasmic and patchy, which is expected rather than a sign of a poor antibody.

An anti mouse cd4 antibody in vivo and in a panel

An anti mouse cd4 antibody is bought either to stain or to deplete, and those are different products: depletion needs an in vivo grade clone with low endotoxin, a stated isotype and a matched control, while staining needs the conjugate and the clone's brightness. The same clone name may exist in both formats, so the grade on the label is what matters.

A wga antibody, and the lectin behind the name

Wheat germ agglutinin is a lectin rather than an antibody, so a wga antibody in a catalogue is either an antibody against the lectin or, more often, a labelled lectin sold beside antibodies because it is used the same way. It binds sialic acid and N-acetylglucosamine, which makes it a membrane and Golgi stain, and enzymatic removal of those sugars is the specificity control.

Common questions

What should a flow cytometry service deliver?

The analysis, the documented gating strategy and the raw acquisition files, along with the control data. A summary table alone cannot be re-examined when a result is surprising.

What controls should be in the scope?

Single stain compensation controls, viability discrimination, fluorescence minus one controls where gates are ambiguous, and an appropriate negative. They consume sample and instrument time, so they must be priced rather than assumed.

How do samples need to be shipped?

According to the stability window for that sample type, with an agreed shipper and courier and a written plan for a late arrival. A sample analysed outside its window produces plausible data that is not valid.

How is drift handled over a long study?

By standardising the instrument with beads on a defined schedule and recording it, with a documented approach to service events. Without that, instrument drift appears as a biological effect.

Who owns flow cytometry panel design, and the flow cytometry panels themselves?

Whoever the agreement says, so settle it before the first sample ships. Establish whether the provider designs the panel, validates one you supply or runs an existing catalogue panel, and who owns the design afterwards: a panel is a real piece of work, and its ownership should not be discovered at the end of a study.

Browse by service class

• Compare Gene synthesis on advertised prices